Is Compounded Tirzepatide Safe? What FDA Has Actually Reported

Nobody can honestly tell you compounded tirzepatide is safe, and nobody can honestly tell you it is dangerous. The vial in your refrigerator has not been through FDA review, so the agency has never evaluated that preparation for safety, effectiveness or quality.^[1] That is a fact about paperwork rather than a finding about harm. What FDA does have is a list of things that have gone wrong, and every item on it is worth knowing before you decide.

What “not FDA-approved” does and does not tell you

Approval is a review of one specific product made one specific way. An approved tirzepatide injection carries a strength printed on a label the agency signed off on, made in a plant held to a standard the agency inspects against, with a safety profile assembled from trials the agency read. A compounded vial has none of that behind it. FDA states the position plainly: compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed.^[1]

Read the second half of that sentence as carefully as the first. Not reviewed is not the same as reviewed and found wanting. Compounding is an ordinary and long-standing part of American pharmacy, and FDA's own explanation of why it exists is unglamorous: a patient allergic to a dye, a child who cannot swallow a tablet, a formulation an approved product simply is not made in.^[2] The question is not whether compounding is legitimate. It is whether the compounded vial you were sold is one of those cases or a cheaper copy of a product that already exists.

Not every compounder is held to the same standard

This is the distinction that decides most of what follows, and almost no seller explains it. Two entirely different kinds of business make compounded drugs in the United States, under two sections of federal law, and only one of them is inspected by FDA against manufacturing rules.

Neither column is the safe one. A 503B facility is inspected against manufacturing standards, which is real, and we have read FDA's own register of them: 98 facilities were listed when we pulled it on August 14, 2026, and 40 of those carried “Not yet inspected”.^[8] A 503A pharmacy that has compounded for one prescriber for twenty years may be scrupulous. What the two columns give you is different questions, and the first one to put to any seller is which of the two made your vial. Our register of the pharmacies behind compounded GLP-1 programs is where we track that answer where we can get it, and we say plainly where we could not.

What FDA has actually reported going wrong

The agency keeps a public page of its concerns with unapproved GLP-1 drugs, and it is specific in a way that seller marketing is not. These are the items on it that touch tirzepatide.^[1]

Dosing errors, from people measuring their own doses

FDA reports multiple adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide. The mechanism it describes is arithmetic: patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating them.^[1] Separately, the agency reports adverse events that may relate to patients being prescribed compounded semaglutide or tirzepatide at doses beyond what the approved label carries — more in a single dose, doses more often, or escalation faster than the label schedule. Some of those were serious. The symptoms that sent people to seek medical attention were the gastrointestinal ones: sickness, vomiting, loose stools, stomach pain, constipation.^[1]

The reason this risk attaches to compounded product specifically is concentration. An approved tirzepatide vial states its strength per milliliter on a label FDA reviewed — the multi-dose Zepbound presentations run from 4.17 mg/mL up to 25 mg/mL, four doses per vial, each printed in the prescribing information.^[9] A compounded vial's concentration is whatever the compounding pharmacy chose, and it is not on any approved label anywhere. Two vials both labeled tirzepatide can require different volumes for the same milligram dose. That is the whole of the error, and it is not exotic.

Labels naming pharmacies that do not exist

FDA says it is aware of fraudulent compounded semaglutide and tirzepatide carrying false information on the label. In some cases the pharmacy named on the label does not exist; in others the label names a real licensed pharmacy that, on the information FDA gathered, did not make the product. The agency reports one adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that had not compounded it, with redness, swelling, pain and a red lump at the injection site.^[1] A pharmacy name on a label is a claim, not a credential, and it is checkable.

Product arriving warm

Injectable GLP-1 drugs need refrigeration, and FDA has received complaints that compounded ones arrived warm or with too little ice to hold temperature. Its advice is not to use an injectable GLP-1 that turns up that way.^[1] This one is easy to check yourself, on the doorstep, and it costs nothing.

Vials sold outside the pharmacy system entirely

FDA has warned companies over unapproved semaglutide, tirzepatide and retatrutide carrying one of two false labels: “for research purposes”, or else “not for human consumption”. The agency says those products went straight to consumers, for human use, with dosing instructions attached.^[1] These are not a discount version of the pharmacy route. There is no pharmacy, no prescription and no license to look up. We treat them separately in what “research use only” actually means. FDA also says it is aware of counterfeit Ozempic in the U.S. market, and it has issued warning letters to stop illegal online sales of semaglutide and tirzepatide.^[1] In our own copy of that letter register, 138 of the 186 letters we track name tirzepatide; they are browsable on our FDA warning letter register.

Salt forms, and where the record actually stops

FDA states that some semaglutide sold by compounders may be a salt form, names semaglutide sodium and semaglutide acetate, and says these are different active ingredients from the one in the approved drugs. It adds that it has no information on whether the salts share the chemical and pharmacologic properties of the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding.^[1]

Here is the part we could not close. That paragraph is about semaglutide. FDA names no tirzepatide salt on it, and we found no FDA page that names one. The nearest the agency comes for tirzepatide is a grouped sentence in its September 5, 2025 announcement of the import green list, which lists “use of unapproved salt forms” among serious concerns it had previously identified with compounded versions of semaglutide and tirzepatide.^[6] So the principle is stated by FDA and the specific named salts are not. If a seller tells you the salt question does not apply to tirzepatide, that is a claim neither of us can check, and the honest thing is to ask which substance the pharmacy bought and from whom.

The legal basis closed, which changes who is still selling

Large-scale tirzepatide compounding was lawful mainly because the drug sat on FDA's shortage list. FDA first determined that shortage resolved on October 2, 2024. Litigation sent the decision back to the agency on October 22, 2024, and on December 19, 2024 FDA issued a new determination that the tirzepatide injection shortage was resolved, allowing 503A pharmacies until February 18, 2025 and outsourcing facilities until March 19, 2025.^[4] A district court denied the compounders' preliminary injunction on March 5, 2025, and the 503A period ended.^[4] As of the agency's April 1, 2026 update, tirzepatide appears on neither the 503B bulks list nor the shortage list, and on April 30, 2026 FDA proposed excluding it from that bulks list outright, finding no clinical need, with comments open to June 29, 2026.^[4][5] The full sequence is in our explanation of which GLP-1s can still be compounded.

The safety consequence is indirect and it is the one most people miss. When a legal basis closes, the operators who cared about it stop, and the ones still shipping at volume are by definition the ones who did not. Compounding for a genuine individual need remains lawful and narrow. A subscription that ships the same formulation to everyone who fills in the same form is not that, and a seller who cannot say on what basis they are still compounding tirzepatide has answered the question.

What nobody can tell you, because it has not been studied

There is no trial of compounded tirzepatide. Not a small one, not a bad one. The efficacy and safety evidence people cite for tirzepatide comes from trials of the approved product, and it does not transfer to a preparation with a different concentration, different excipients and, in some cases, a different route.

The closest thing to a survey of what is actually being sold was published in 2026 in Annals of Pharmacotherapy. Pharmacy researchers searched compounder websites in February and March 2025 and cataloged 33 distinct products; one-third of them contained tirzepatide. Their finding on documentation is the one worth carrying: only 18 percent of the products they included published a beyond-use date and preferred storage conditions.^[7] MEDLINE indexes that paper as an editorial, so it is a structured look at a market with the authors' judgment attached, not a measurement of anything in a patient. That is the honest ceiling of the published record here.

• No published trial tests a compounded tirzepatide formulation against the approved product, or against anything else.
• No published dataset characterizes what an added excipient does in an injectable tirzepatide preparation.
• No comparative harm rate can be computed, because 503A reporting to FDA is not required.^[1]

Five questions that get you a real answer

1. Which pharmacy made this, 503A or 503B, and what is its license number? A seller who will not name the compounder is telling you something. A named 503B facility can be looked up on FDA's own register.^[8]
2. On what legal basis is it being compounded now? Tirzepatide is not on the shortage list and not on the 503B bulks list.^[4] The answer should be about an individual clinical need, and it should be a real sentence.
3. What is the concentration in milligrams per milliliter, and how many units is my dose? Ask in the units printed on the syringe you were sent. This is exactly the arithmetic behind the reported dosing errors.^[1]
4. What else is in the vial besides tirzepatide? Added ingredients are common in this market,^[7] and what they do in an injectable GLP-1 is not characterized. Our look at the B12 in compounded semaglutide works through the same question on the other molecule.
5. Who do I call at 9pm if something is wrong? If the answer is a chat widget rather than a clinician, the accountability gap is the product you bought.

If you are weighing this against the approved product, the comparison worth doing is the current one rather than the one you formed a year ago. We keep dated figures for every seller we track on the price tracker, and our ranked board for compounded tirzepatide records what each program will and will not tell you about its pharmacy.